Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)

摘要: Many prognostic factors have been identified in chronic lymphocytic leukaemia (CLL). Based on the assessment of B cell receptor (BCR) structure and function, a subdivision into subtypes is possible (e.g., immunoglobulin heavy chain variable gene segment (IGHV) unmutated mutated, V3-21 usage) with distinct biological clinical characteristics. Recurrent genomic aberrations (i.e., 11q 17p deletion) mutations TP53 ATM ) help to define subgroups. In addition, serum markers thymidine kinase (TK) s2-microglobulin (s2-MG)), cellular CD38 ZAP70) staging an impact outcome CLL. The characterisation CLL has not only led progress prediction but also begun be translated novel treatment strategies. Nonetheless, most associated prognosis thoroughly interrogated for their predictive value light different therapeutic approaches. With growing number agents acting specific targets being used situations, future likely bring identification